IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 26.41 (+4.29), BIIB: 305.69 (+4.11), KITE: 31.85 (+0.55), FWP: 17.50 (-1.49), XENE: (), ATRA: (), VBAY: (), GWB: 18.00 (+0.10)
Major Averages Pare Losses, Then Head Lower Again
at Investor's Business Daily - Wed Oct 15, 11:01AM CDT
Stocks headed lower again in late-morning trade after paring steep early losses sparked by weak economic data. The S&P 500 and Dow industrials sank 1.5% each, while the Nasdaq was down 1.3%. The tech-heavy index had earlier narrowed its deficit to...
AMBA: 38.60 (+2.94), BIIB: 305.69 (+4.11), CAVM: 43.12 (+3.25), NTES: 88.99 (+3.13), NXPI: 58.61 (+2.03), INTC: 31.27 (-0.87)
Biogen Idec and Gretchen Rubin Unveil MS Blueprint(TM), a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
Business Wire - Wed Oct 15, 7:01AM CDT
Living with a chronic condition like multiple sclerosis (MS) can be overwhelming for individuals and caregivers who have to balance the challenges of everyday life and work while juggling regular doctors' visits and medications. To support people living with MS, Biogen Idec (NASDAQ:BIIB) has launched MS Blueprint(TM), a new program that encourages those impacted by MS to focus on activities that may bring joy to their lives every day. By visiting MSBlueprint.com, people can set goals, create personalized MS Blueprints, and take small steps toward a more positive life.
BIIB: 305.69 (+4.11)
IBD 50: Medical, Internet Companies Top Q3 Estimates
at Investor's Business Daily - Mon Oct 13, 6:15PM CDT
Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter...
AMBA: 38.60 (+2.94), BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), VIPS: 185.68 (+8.98), YY: 72.40 (+2.93), SWKS: 49.60 (+0.69), FB: 73.21 (-0.38), AKRX: 34.95 (-0.31), KSU: 115.57 (+0.43), SLXP: 132.42 (-1.16), ATHM: 45.12 (+2.63), LCI: 40.30 (-0.36), ABC: 76.02 (-0.61), GILD: 96.16 (-1.02), AVGO: 72.55 (+0.53)
Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Isis Pharmaceuticals (ISIS) announced positive results from phase II studies on ISIS-SMNRx.
MDVN: 89.63 (-1.68), BIIB: 305.69 (+4.11), ISIS: 38.97 (+2.13), LGND: 46.28 (+0.45)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 4.25% Loss
Comtex SmarTrend(R) - Mon Oct 13, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.99 to a high of $315.75. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $312.00 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.69 (+4.11)
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 26.41 (+4.29), BIIB: 305.69 (+4.11), FWP: 17.50 (-1.49), KITE: 31.85 (+0.55), XENE: (), MRK: 54.73 (-1.60), CFG: 21.85 (-0.60), ZAYO: (), ATRA: (), TEVA: 50.09 (+0.19), VBAY: (), GWB: 18.00 (+0.10)
Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire
PR Newswire - Mon Oct 13, 7:30AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.
HCA: 64.84 (-2.14), BIIB: 305.69 (+4.11), ARWR: 6.47 (+0.59), SHPG: 170.49 (-74.08), SLXP: 132.42 (-1.16)
1 Huge Risk Facing This Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 11:02AM CDT
Source: GW Pharmaceuticals The prospects for medical marijuana are incredibly intriguing. According to a Medical Marijuana Markets report in 2011, the market for medical marijuana may surge from $1.7 billion in that same year to as much as $9...
BIIB: 305.69 (+4.11), GWPH: 61.55 (-3.65), SNY: 51.50 (-0.75), NVS: 86.22 (-0.65)
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe
Thomson Reuters ONE - Thu Oct 09, 2:01PM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that Biogen Idec has submitted a Marketing Authorisation Application (MAA) for Elocta (rFVIIIFc) to the European Medicines Agency (EMA). Sobi has an exclusive opt-in right to assume final development and commercialisation of Elocta in Europe, Russia, the Middle East and Northern Africa.
BIIB: 305.69 (+4.11)
Global Biological Drugs Market Outlook 2020
M2 - Thu Oct 09, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv5tsf/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market. Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/sv...ical_drugs
BIIB: 305.69 (+4.11), ABT: 40.01 (-1.05), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), BMY: 48.96 (+0.04), NVS: 86.22 (-0.65)
CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Wed Oct 08, 3:01PM CDT
Second paragraph, first sentence of release dated September 25, 2014 should read: Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. (instead of Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 9:00 am ET.).
BIIB: 305.69 (+4.11)
5 States Expected to See the Biggest Increase in Alzheimer's Disease
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 05, 10:07AM CDT
Source: Centers for Disease Control and Prevention. Cancer and heart disease may be far more prevalent killers, but Alzheimer's disease is certainly no ailment to overlook, considering that it's the eighth leading cause of death in the United...
BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), PFE: 28.19 (-0.27), LLY: 62.87 (-0.27)
The Next Blue-Chip Stocks: Biogen Idec
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 04, 10:32AM CDT
Becoming the next blue chip stock isn't easy, especially in a high risk, high reward sector like biotech. But once you get to be as big as Biogen Idec , blue chip status is the next obvious step. BIIB data by YCharts Solid revenue...
BIIB: 305.69 (+4.11), AMGN: 130.90 (-1.30)
Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 305.69 (+4.11), PRGO: 145.85 (-1.33), ABAX: 48.07 (+0.20), HAE: 35.62 (+0.16)
Insider Trading Alert - BIIB, RKUS And PF Traded By Insiders
at The Street - Fri Oct 03, 9:30AM CDT
Stocks with insider trader activity include BIIB, RKUS and PF
BIIB: 305.69 (+4.11), PF: 32.12 (-0.56), RKUS: 11.68 (+0.37)
Global Cancer Monoclonal Antibodies Market & Pipeline Insight 2014
M2 - Fri Oct 03, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l88677/global_cancer) has announced the addition of the "Global Cancer Monoclonal Antibodies Market & Pipeline Insight" report to their offering. A significant amount of research is being carried out currently to improve the level of potency of monoclonal antibodies. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers, mostly monoclonal antibodies. However, still a lot of work needs to be done in this arena. Though the monoclonal antibodies have already emerged as significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful. Additionally, the pharma companies are also researching on ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body's immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions. It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. The future of mAbs for cancer continues to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human cells there is still significant work which needs to be done. Global Cancer Monoclonal Antibodies Market & Pipeline Insight Report highlights: - Cancer Monoclonal Antibodies Market Overview - Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook - Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country - Cancer Monoclonal Antibodies in Pipeline: 605 - Majority Cancer Monoclonal Antibodies Preclinical Phase: 258 - Marketed Cancer Monoclonal Antibodies: 34 - Cancer Monoclonal Antibodies Patent Analysis Key Topics Covered: 1. Introduction to Monoclonal Antibodies 2. Types of Monoclonal Antibodies 3. Mechanisms of Monoclonal Antibodies 4. Need for Monoclonal Antibodies for Cancer Treatment 5. Cancer Monoclonal Antibodies Market Overview 6. Cancer Monoclonal Antibodies Market Dynamics 7. Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country 8. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 9. Suspended & Discontinued Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country 10. Competitive Landscape - Abbvie - Amgen - Bayer HealthCare - Biogen Idec - Eli Lilly - Genmab - Gilead Sciences - GlaxoSmithKline - Novartis - Pfizer - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/l8...bal_cancer
BIIB: 305.69 (+4.11), GILD: 96.16 (-1.02), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), NVS: 86.22 (-0.65)
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead
at Investor's Business Daily - Thu Oct 02, 5:25PM CDT
While the stock market clocked a slight gain in the last full month of summer, the uptrend was under pressure during the second half of September. Managers of top-performing funds the past three months continued to add shares of medical issues during...
FDX: 153.82 (+0.10), BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), FB: 73.21 (-0.38), SLXP: 132.42 (-1.16), WSM: 63.71 (-0.42), CELG: 86.55 (+0.07), LUV: 30.02 (+0.02), AGN: 177.59 (-4.40), DLTR: 55.24 (-0.64), GILD: 96.16 (-1.02), CMG: 647.38 (-3.79), JAZZ: 146.31 (+2.58), COST: 124.30 (-1.95), CVS: 78.99 (-1.69), ULTA: 110.28 (-1.68), UNP: 99.70 (-0.46)